Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "renal-disease"

18 News Found

Bayer’s pharma growth strategy progressing well as pipeline advances
News | January 15, 2025

Bayer’s pharma growth strategy progressing well as pipeline advances

Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid


Lupin launches Bumetanide Injection USP in US
News | November 20, 2024

Lupin launches Bumetanide Injection USP in US

Bumetanide Injection USP (RLD Bumex) had an estimated annual sale of USD 20 million in the US


Lupin receives USFDA approval for Bumetanide Injection
Drug Approval | September 19, 2024

Lupin receives USFDA approval for Bumetanide Injection

Bumetanide Injection USP (RLD Bumex) had estimated annual sales of USD 20 million in the U.S.


Novartis and Versant to form biotech venture Borealis Biosciences
Biotech | August 23, 2024

Novartis and Versant to form biotech venture Borealis Biosciences

Novartis has option to acquire two future development-ready programs to augment its renal portfolio, a strategic area of focus for the company


Nephro Care India reports 86.07% jump in PAT at Rs 4.41 crore during FY 23-24
News | August 23, 2024

Nephro Care India reports 86.07% jump in PAT at Rs 4.41 crore during FY 23-24

Higher revenues backed by huge demand and expanding network contributed to the growth in bottom line


Pfizer announces results of ABRYSVO for RSV in immunocompromised adults
Diagnostic Center | August 13, 2024

Pfizer announces results of ABRYSVO for RSV in immunocompromised adults

These results add to the growing body of evidence indicating a single dose of ABRYSVO provides strong immune protection against outcomes caused by RSV


Supernova Phase III trial of sipavibart long-acting antibody met primary endpoints in preventing COVID-19
Diagnostic Center | May 20, 2024

Supernova Phase III trial of sipavibart long-acting antibody met primary endpoints in preventing COVID-19

SUPERNOVA is a large Phase III global trial providing the only efficacy data in immunocompromised patients


Roche and Alnylam report positive topline results from Phase 2 study KARDIA-1 of zilebesiran
Diagnostic Center | September 11, 2023

Roche and Alnylam report positive topline results from Phase 2 study KARDIA-1 of zilebesiran

Zilebesiran demonstrated an encouraging safety and tolerability profile in adult patients with mild-to-moderate hypertension


Everest Medicines partners with Shanghai Pharma Subsidiary to accelerate the commercialization of XERAVA in Mainland China
News | April 19, 2023

Everest Medicines partners with Shanghai Pharma Subsidiary to accelerate the commercialization of XERAVA in Mainland China

Everest and SPH Kyuan will work closely to promote import and channel distribution of XERAVA in China